Ladenburg Thalmann Downgrades Stemline Therapeutics (STML) to Neutral
Tweet
Share
E-mailGet Alerts STML Hot Sheet
Price: $11.83 --0%
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
6 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Ladenburg Thalmann downgraded Stemline Therapeutics (NASDAQ: STML) from Buy to Neutral.
For an analyst ratings summary and ratings history on Stemline Therapeutics click here. For more ratings news on Stemline Therapeutics click here.
Shares of Stemline Therapeutics closed at $12.11 yesterday.
You May Also Be Interested In
- JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
- Leerink Partners Downgrades CureVac (CVAC) to Market Perform
- Truist Securities Double Downgrades Monster Beverage (MNST) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
